# Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

> **NCT02198482** · PHASE2 · TERMINATED · sponsor: **University of Ulm** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Volasertib
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT02198482
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems
- **Last updated:** 2018-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02198482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02198482, "Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02198482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*